File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer

TitleA randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer
Authors
Issue Date1989
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/CHE
Citation
Chemotherapy, 1989, v. 35 n. 3, p. 221-227 How to Cite?
AbstractA randomized clinical study of patients with advanced epithelial ovarian cancer after debulking surgery showed that high-dose (120 mg/m 2) cis-platinum (DDP) in combination with cyclophosphamide (600 mg/m 2) had a significantly higher response and survival rate than the low-dose DDP (60 mg/m 2) and cyclophosphamide combination. The 3-year actuarial survival rate of the high-dose group was 60% and that of the low-dose group was 30%. Though moderate to severe marrow toxicity was evident in 80% of the patients in the high-dose group and 40% of the low-dose group, no serious sepsis or death developed as a result of the marrow depression. Mild neurotoxicity was observed in 55% of the patients in the high-dose group and only 20% in the low-dose group. Mild nephrotoxicity was seen in 25 and 17% of patients in the high- and low-dose groups, respectively. It was concluded that the 120 mg/m 2 dose DDP and cyclophosphamide combination should be used in the treatment of carcinoma of the ovary in spite of its toxicities. However, it should only be used in institutions with supportive facilities in the management of patients with severe marrow depression.
Persistent Identifierhttp://hdl.handle.net/10722/147832
ISSN
2015 Impact Factor: 0.992
2015 SCImago Journal Rankings: 0.630
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorChoo, YCen_HK
dc.contributor.authorCheung, Men_HK
dc.contributor.authorWong, LCen_HK
dc.contributor.authorMa, HKen_HK
dc.contributor.authorCollins, Ren_HK
dc.contributor.authorFung, Cen_HK
dc.contributor.authorNg, CSen_HK
dc.contributor.authorWong, Ven_HK
dc.contributor.authorHo, HCen_HK
dc.contributor.authorLeung, Pen_HK
dc.contributor.authorWong, Ren_HK
dc.contributor.authorChan, Een_HK
dc.contributor.authorSimon, MTPen_HK
dc.contributor.authorHo, LCen_HK
dc.contributor.authorChan, YFen_HK
dc.date.accessioned2012-05-29T06:09:27Z-
dc.date.available2012-05-29T06:09:27Z-
dc.date.issued1989en_HK
dc.identifier.citationChemotherapy, 1989, v. 35 n. 3, p. 221-227en_HK
dc.identifier.issn0009-3157en_HK
dc.identifier.urihttp://hdl.handle.net/10722/147832-
dc.description.abstractA randomized clinical study of patients with advanced epithelial ovarian cancer after debulking surgery showed that high-dose (120 mg/m 2) cis-platinum (DDP) in combination with cyclophosphamide (600 mg/m 2) had a significantly higher response and survival rate than the low-dose DDP (60 mg/m 2) and cyclophosphamide combination. The 3-year actuarial survival rate of the high-dose group was 60% and that of the low-dose group was 30%. Though moderate to severe marrow toxicity was evident in 80% of the patients in the high-dose group and 40% of the low-dose group, no serious sepsis or death developed as a result of the marrow depression. Mild neurotoxicity was observed in 55% of the patients in the high-dose group and only 20% in the low-dose group. Mild nephrotoxicity was seen in 25 and 17% of patients in the high- and low-dose groups, respectively. It was concluded that the 120 mg/m 2 dose DDP and cyclophosphamide combination should be used in the treatment of carcinoma of the ovary in spite of its toxicities. However, it should only be used in institutions with supportive facilities in the management of patients with severe marrow depression.en_HK
dc.languageengen_US
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/CHEen_HK
dc.relation.ispartofChemotherapyen_HK
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshCisplatin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshCyclophosphamide - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshKidney - Drug Effectsen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOvarian Neoplasms - Drug Therapyen_US
dc.subject.meshRandom Allocationen_US
dc.titleA randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian canceren_HK
dc.typeArticleen_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.emailCollins, R:rcollins@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.identifier.authorityCollins, R=rp00251en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2766862-
dc.identifier.scopuseid_2-s2.0-0024334981en_HK
dc.identifier.volume35en_HK
dc.identifier.issue3en_HK
dc.identifier.spage221en_HK
dc.identifier.epage227en_HK
dc.identifier.isiWOS:A1989AE14600011-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridChoo, YC=7102874233en_HK
dc.identifier.scopusauthoridCheung, M=7201897430en_HK
dc.identifier.scopusauthoridWong, LC=7402092003en_HK
dc.identifier.scopusauthoridMa, HK=7403095603en_HK
dc.identifier.scopusauthoridCollins, R=7403350455en_HK
dc.identifier.scopusauthoridFung, C=36831468800en_HK
dc.identifier.scopusauthoridNg, CS=36747471100en_HK
dc.identifier.scopusauthoridWong, V=24381178900en_HK
dc.identifier.scopusauthoridHo, HC=36777870600en_HK
dc.identifier.scopusauthoridLeung, P=55085128400en_HK
dc.identifier.scopusauthoridWong, R=55230037400en_HK
dc.identifier.scopusauthoridChan, E=7401994013en_HK
dc.identifier.scopusauthoridSimon, MTP=7404410468en_HK
dc.identifier.scopusauthoridHo, LC=36784946500en_HK
dc.identifier.scopusauthoridChan, YF=7403676061en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats